Moderna (MRNA) Cost of Revenue (2020 - 2026)

Moderna (MRNA) has 7 years of Cost of Revenue data on file, last reported at $955.0 million in Q1 2026.

• On a quarterly basis, Cost of Revenue rose 961.11% year-over-year to $955.0 million in Q1 2026; TTM through Mar 2026 was $1.7 billion, a 18.86% increase from a year earlier, with the FY2025 full-year figure at $868.0 million, down 40.71% from the prior year.
• Cost of Revenue for Q1 2026 stood at $955.0 million, up from $452.0 million in the prior quarter.
• Over the last five years, Cost of Revenue for MRNA reached as high as $2.2 billion in Q3 2023 and fell as low as $90.0 million in Q1 2025.
• Historically, Cost of Revenue has averaged $698.7 million across 5 years, with a median of $731.0 million in 2023.
• Across the five-year window, Cost of Revenue sank 87.88% in 2024 and jumped 961.11% in 2026, its largest moves.
• Year by year, Cost of Revenue stood at $400.0 million in 2022, then soared by 132.25% to $929.0 million in 2023, then fell by 20.45% to $739.0 million in 2024, then slumped by 38.84% to $452.0 million in 2025, then soared by 111.28% to $955.0 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $955.0 million in Q1 2026, $452.0 million in Q4 2025, and $207.0 million in Q3 2025.